Skip to main content
SKYE logo

Skye Bioscience, Inc.

SKYENASDAQHealthcareBiotechnology

$1.57Today:- (-)1Y +11.72%

As of Oct 26, 2026 close

Market cap
$62.32M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.57$7.04
Volume (live)
-
Avg. volume (3M)
47.72K

Skye Bioscience (SKYE) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Skye Bioscience used $43.06M of cash in operating activities and spent $6.31K on capital expenditures. That left free cash flow of −$43.07M.

Skye Bioscience Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Skye Bioscience, Inc. (SKYE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-55.92-26.57-37.64-19.48-8.52-6.561.05-19.19-3.09
Depreciation & Amortization0.720.300.120.110.030.000.000.000.01
Deferred Income Tax0.000.000.000.000.000.00-8.690.000.00
Stock Based Compensation7.778.320.990.630.870.300.680.670.61
Change in Working Capital4.73-2.63-0.47-0.760.650.090.300.10-0.32
Change in Accounts Payable1.40-0.59-0.700.800.520.240.13-0.09-0.17
Change in Other Working Capital3.34-3.640.230.030.59-0.150.160.19-0.15
Other Operating Activities-0.36-3.6423.056.760.590.110.6314.47-0.50
Net Cash from Operating Activities-43.06-25.24-13.95-12.74-6.47-6.05-6.03-3.94-3.30
Investing Activities
Capital Expenditures-0.01-1.60-0.01-0.09-0.09-0.010.000.00-0.02
Acquisitions0.000.000.005.310.000.000.000.000.00
Purchases of Investments-19.850.000.000.000.000.000.000.000.00
Sales/Maturities of Investments0.361.360.000.000.000.000.000.000.00
Other Investing Activities0.000.006.615.240.000.000.000.000.00
Net Cash from Investing Activities-19.50-0.256.605.21-0.09-0.010.000.00-0.02
Financing Activities
Debt Repayment0.000.004.71-0.890.000.570.012.350.50
Common Stock Issued0.0383.5611.730.006.066.091.923.100.19
Other Financing Activities0.00-6.43-0.010.00-0.940.054.080.103.01
Net Cash from Financing Activities0.0383.5616.44-0.2113.086.706.005.543.51
Summary
Net Change in Cash-62.5358.089.09-7.746.510.64-0.021.590.20
Cash at Beginning of Period68.4210.341.258.992.471.831.860.260.06
Cash at End of Period5.8868.4210.341.258.992.471.831.860.26
Free Cash Flow-43.07-26.84-13.96-12.84-6.57-6.06-6.03-3.95-3.32
Supplemental Disclosures
Interest Paid-0.430.200.330.040.12---
Income Taxes Paid-0.010.000.010.000.00---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Skye Bioscience Cash Flow

What is Skye Bioscience's free cash flow?

Skye Bioscience had negative free cash flow of $43.07M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$43.06M minus $6.31K of capital expenditures.

How much does Skye Bioscience spend on capital expenditures?

Skye Bioscience spent $6.31K on capital expenditures in fiscal 2025, compared with $1.60M a year earlier.

Does Skye Bioscience pay dividends or buy back shares?

Skye Bioscience's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition